. Author manuscript; available in PMC: 2013 Dec 15.

Published in final edited form as: J Acquir Immune Defic Syndr. 2011 Mar 1;56(0 1):10.1097/QAI.0b013e3182097537. doi: 10.1097/QAI.0b013e3182097537

Table 4.

Process Data on Office-based Treatment of HIV Infected Patients Receiving Buprenorphine/naloxone or Methadone

Variable	Mean (SD), median, range
Buprenorphine/naloxone dose
Quarter 1	16.9 (6.6), 16, 2–40
Quarter 2	17.1 (7.3), 16, 2–44
Quarter 3	17.5 (6.8), 16, 2–40
Quarter 4	18.2 (7.1), 16, 2–44
Number of buprenorphine/naloxone-related office visits
Quarter 1	7.1 (7.3), 5, 0–39
Quarter 2	5.9 (7.0), 4, 0–39
Quarter 3	7.3 (9.3), 4, 0–50
Quarter 4	5.3 (6.9), 3, 0–38
Number of urine toxicologies obtained
Quarter 1	3.8 (3.8), 3, 0–14
Quarter 2	2.7 (3.1), 2, 0–16
Quarter 3	2.7 (3.3), 2, 0–16
Quarter 4	1.5 (2.2), 1, 0–12